Literature DB >> 24107389

Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.

O Gasch1, M Camoez, M A Domínguez, B Padilla, V Pintado, B Almirante, C Martín, F López-Medrano, E Ruiz de Gopegui, J R Blanco, G García-Pardo, E Calbo, M Montero, A Granados, A Jover, C Dueñas, M Pujol.   

Abstract

Entities:  

Keywords:  MICs; bloodstream infections; cationic peptides; outcomes

Mesh：

Substances：

Year:  2013        PMID： 24107389     DOI： 10.1093/jac/dkt396

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  26 in total

1.  Impact of daptomycin resistance on Staphylococcus aureus virulence.

Authors:  David R Cameron; Lawrence I Mortin; Aileen Rubio; Eleftherios Mylonakis; Robert C Moellering; George M Eliopoulos; Anton Y Peleg
Journal:  Virulence       Date:  2015       Impact factor: 5.882

2.  The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance?

Authors:  Cristina El Haj; Oscar Murillo; Alba Ribera; Dolors Garcia-Somoza; Fe Tubau; Carmen Cabellos; Javier Cabo; Javier Ariza
Journal:  Med Microbiol Immunol       Date:  2016-09-17       Impact factor: 3.402

3.  Evolution and single-nucleotide polymorphisms in methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to vancomycin and daptomycin, based on determination of the complete genome.

Authors:  Tetsuo Yamaguchi; Shingo Suzuki; Sakiko Okamura; Yuri Miura; Ayaka Tsukimori; Itaru Nakamura; Norihiko Ito; Anri Masuya; Takashi Shiina; Tetsuya Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

4.  In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.

Authors:  Jeshina Janardhanan; Jayda E Meisel; Derong Ding; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 5.  Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

Authors:  Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

Review 6.  Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Authors:  Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler
Journal:  Nat Rev Microbiol       Date:  2019-04       Impact factor: 60.633

7.  Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Evan J Zasowski; Trang D Trinh; Kimberly C Claeys; Anthony M Casapao; Noor Sabagha; Abdalhamid M Lagnf; Kenneth P Klinker; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

8.  Imipenem plus Fosfomycin as Salvage Therapy for Vertebral Osteomyelitis.

Authors:  Itaru Nakamura; Tetsuo Yamaguchi; Kotaro Aoki; Yuri Miura; Satoko Sato; Hiroaki Fujita; Hidehiro Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

9.  Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.

Authors:  Andrew D Berti; Sarah L Baines; Benjamin P Howden; George Sakoulas; Victor Nizet; Richard A Proctor; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

10.  In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Authors:  Alexander J Lepak; Ajit Parhi; Michaela Madison; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.